A Phase 3 Multi-Center Randomized Double-Blind Placebo-Controlled Study of Fostamatinib Disodium in the Treatment of wAIHA
-
- STATUS
- Recruiting
-
- participants needed
- 90
-
- sponsor
- Rigel Pharmaceuticals
Updated on 14 August 2022
Huyen Tran, MD
Primary Contact
The Alfred Hospital (6.2 mi away) Contact
+125 other locationSummary
The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Details
| Condition | Warm Antibody Autoimmune Hemolytic Anemia |
|---|---|
| Treatment | Placebo, Fostamatinib disodium |
| Clinical Study Identifier | NCT03764618 |
| Sponsor | Rigel Pharmaceuticals |
| Last Modified on | 14 August 2022 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer